Praxis Precision Medicines, Inc. Income Statement
PRAX / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Praxis Precision Medicines, Inc. reported $0 in revenue and $303M in net loss for FY2025. Revenue increased 249.5% from FY2023 to FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 4.48 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $8.6M | $2.4M | $0 | - | - | - |
| SG&A Expense | $59.1M | $56.3M | $42.1M | $59.9M | $47.1M | $17.0M | $6.2M |
| R&D Expense | $267.1M | $152.4M | $86.8M | $155.0M | $120.3M | $45.0M | $29.6M |
| Operating Income | -$326.2M | -$200.2M | -$126.4M | -$215.0M | -$167.3M | -$62.0M | -$35.8M |
| Income Tax | $471.0K | - | - | - | $0 | -$8.0K | -$84.0K |
| Net Income | -$303.3M | -$182.8M | -$123.3M | -$214.0M | -$167.1M | -$61.8M | -$35.5M |
| EPS (Basic) | -$18.69 | -$18.69 | -$69.65 | -$69.65 | -$3.94 | -$7.86 | - |
| EPS (Diluted) | -$18.69 | -$18.69 | -$69.65 | -$69.65 | -$3.94 | -$7.86 | - |
| Shares Outstanding | 19.4M | 8.8M | 3.3M | 3.1M | 42.5M | 9.0M | 1.5M |
| Operating Margin | - | -2340.3% | -5164.4% | - | - | - | - |
| Profit Margin | - | -2137.5% | -5037.9% | - | - | - | - |